Light exposure during sleep impairs cardiometabolic function
Due to their glucose-dependent mechanisms of insulin secretion augmentation and glucagon suppression, GLP-1 RAs are able to effectively improve glycemic control in T2DM patients without substantially increasing the risk of hypoglycemia [1]
Focus on high-quality delivery systems rather than simply chasing the highest milligram count
This is a significant concern, as administering such treatments requires a deep understanding of human anatomy and medical training to avoid complications
It works through GLP-1 receptor agonism, affecting insulin secretion and appetite signaling, not urinary glucose levels
Unlike semaglutide (a large peptide requiring specialized absorption technology), orforglipron is a small molecule that absorbs more reliably through the GI tract, can be taken with food, and is cheaper to manufacture